Lava Therapeutics B.v Stock Insider Trading

Healthcare > Biotechnology

Buy LVTX

*Your capital is at risk

$1.74

+0 (+0%)

At Close: Feb 27, 2026

Lava Therapeutics B.V Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -61.07. In total, the insiders bought 4.7M and sold 9.31M LVTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-61.07
● Buy	4.7M shares
● Sell	9.31M shares
58% Buy Activity Moderate Negative Correlation
Sell Signal High Confidence Sep 18, 2025 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -61.07. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Sep 19, 2025 Sell	Common Stock S-Sale	Versant Venture Capital Vi, L.p. 10 Percent Owner	10% Owner	532 870 Value: $746.8K
Sep 19, 2025 Sell	Common Stock S-Sale	Versant Venture Capital Vi, L.p. 10 Percent Owner	10% Owner	532 870 Value: $746.8K
Sep 18, 2025 Sell	Common Stock S-Sale	Versant Venture Capital Vi, L.p. 10 Percent Owner	10% Owner	366 111 Value: $527.9K
Sep 18, 2025 Sell	Common Stock S-Sale	Versant Venture Capital Vi, L.p. 10 Percent Owner	10% Owner	228 791 Value: $329.9K
Sep 18, 2025 Sell	Common Stock S-Sale	Versant Venture Capital Vi, L.p. 10 Percent Owner	10% Owner	366 111 Value: $527.9K
Sep 18, 2025 Sell	Common Stock S-Sale	Versant Venture Capital Vi, L.p. 10 Percent Owner	10% Owner	228 791 Value: $329.9K
Sep 17, 2025 Sell	Common Stock S-Sale	Versant Venture Capital Vi, L.p. 10 Percent Owner	10% Owner	362 806 Value: $540.3K
Sep 17, 2025 Sell	Common Stock S-Sale	Versant Venture Capital Vi, L.p. 10 Percent Owner	10% Owner	226 726 Value: $337.6K
Sep 17, 2025 Sell	Common Stock S-Sale	Versant Venture Capital Vi, L.p. 10 Percent Owner	10% Owner	362 806 Value: $540.3K
Sep 17, 2025 Sell	Common Stock S-Sale	Versant Venture Capital Vi, L.p. 10 Percent Owner	10% Owner	226 726 Value: $337.6K
Sep 16, 2025 Sell	Common Stock S-Sale	Versant Venture Capital Vi, L.p. 10 Percent Owner	10% Owner	307 707 Value: $471.8K
Sep 16, 2025 Sell	Common Stock S-Sale	Versant Venture Capital Vi, L.p. 10 Percent Owner	10% Owner	192 293 Value: $294.8K
Sep 16, 2025 Sell	Common Stock S-Sale	Versant Venture Capital Vi, L.p. 10 Percent Owner	10% Owner	307 707 Value: $471.8K
Sep 16, 2025 Sell	Common Stock S-Sale	Versant Venture Capital Vi, L.p. 10 Percent Owner	10% Owner	192 293 Value: $294.8K
Feb 13, 2025 Buy	Common Shares (Right to Buy) A-Award	Wilson Karen J Director	Director	33 390 Value: $31.1K
Feb 13, 2025 Buy	Common Shares (Right to Buy) A-Award	Wadlinger Mary E. Director	Director	33 390 Value: $31.1K
Feb 13, 2025 Buy	Common Shares (Right to Buy) A-Award	Noble James Director	Director	33 390 Value: $31.1K
Feb 13, 2025 Buy	Common Shares (Right to Buy) A-Award	Kiener Peter A Director	Director	33 390 Value: $31.1K
Feb 13, 2025 Buy	Common Shares (Right to Buy) A-Award	Backstrom Jay T. Director	Director	33 390 Value: $31.1K
Feb 13, 2025 Buy	Common Shares (Right to Buy) A-Award	Dhingra Kapil Director	Director	33 390 Value: $31.1K
Feb 13, 2025 Buy	Share Options (Right to Buy) A-Award	Powell Fred M Chief Financial Officer	C-Suite Officer	124 700 Value: $116.0K
Feb 13, 2025 Buy	Share Options (Right to Buy) A-Award	Morris Charles Q Chief Medical Officer	Officer	130 850 Value: $121.7K
Feb 13, 2025 Buy	Common Shares (Right to Buy) A-Award	Oliger Christy J. Director	Director	33 390 Value: $31.1K
Feb 13, 2025 Buy	Share Options (Right to Buy) A-Award	Hurly Stephen A Chief Executive Officer	CEO / President	335 100 Value: $311.6K
Feb 13, 2025 Buy	Common Shares (Right to Buy) A-Award	Wilson Karen J Director	Director	33 390 Value: $31.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT LAVA THERAPEUTICS B.V.

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for b...

Read Full Profile Here